---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004428"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-07-01T21:00:22+00:00"
generated_at: "2026-07-01T21:02:12.556752+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports tovecimig Phase 2/3 COMPANION-002 met primary endpoint; BLA filing planned

## Summary
- Tovecimig + paclitaxel achieved ORR 18.0% vs 5.3% paclitaxel alone (p=0.0228); median PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001).
- OS analysis confounded by 54% crossover; post-hoc subset shows median OS 12.8 mo for crossover patients vs 6.1 mo for no-crossover (HR=0.54, p=0.04).
- Cash and marketable securities $195M as of Q1 2026; runway into 2028. FDA meeting expected Q3 2026, BLA filing late 2026, potential approval 2H 2027.
- Pipeline includes CTX-8371 (PD-1xPD-L1) with deep responses in TNBC, HL, NSCLC; CTX-471 (CD137) Phase 2 in NCAM+ tumors mid-2026.

## SEC filing metadata
- accession: 0001171843-26-004428
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-07-01T21:00:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/0001171843-26-004428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/f8k_070126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004428
- JSON: https://secwatch.observer/filing/0001171843-26-004428.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.